(Isstories Editorial):- Barcelona, Spain Oct 8, 2025 (Issuewire.com) – ABCDx, a health tech startup developing next-generation emergency brain diagnostics, today announced the launch of a groundbreaking pilot study in collaboration with Charité, Universitätsmedizin Berlin, one of Europe’s leading university hospitals and the Geneva University as study partners.
Globally, one in four people over the age of 25 will suffer a stroke in their lifetime (World Stroke Organization). The deadliest are large vessel occlusions (LVO), which cause 95% of the stroke-related disability and deaths. Each minute without treatment costs nearly 2 million brain cells.
A lifesaving treatment exists: thrombectomy, a procedure that removes the clot within hours of onset. Yet access is limited, only about 3,000 centres worldwide can perform it, and too many patients arrive too late.
More on Isstories:
- Catherine Bierwith, Recognized by BestAgents.us as a 2025 Top Agent
- A Leader in Concierge Medicine: Heather M. Peña, MD, Pioneers Healthy Aging and Preventive Care in Napa Valley
- Josering M. Alobwede, IPDH, Aims to Revolutionize Dental Care in Portland, Maine
- Introducing Chalon Lefebvre, PT, LMT, CSCS: Founder of Kinetic Response Physical Therapy
- Asma Iftikhar, MD, FCCP: Leading Pulmonary and Critical Care Across the North Shore
ABCDx has developed a novel blood test designed to support faster stroke triage. With a single drop of blood, the test is intended to predict LVO stroke directly in the ambulance in 10 minutes, so paramedics can triage the patient straight to the right hospital. Preliminary evaluations indicate this approach could save considerable time, enabling faster access to thrombectomy, which may improve survival and reduce long-term disability.
But this pilot goes beyond the test strip. It is the real-world study of the full ABCDx stroke triage platform, which brings together:
-A rapid blood test with LVO stroke patented biomarkers
–A mobile app that guides paramedics and reads the result
–An AI algorithm that combines blood data with patient-specific clinical information
-A secure communication platform that transmits results straight to the hospital
This end-to-end platform is being evaluated under real-life emergency conditions to prepare for CE marking and clinical deployment across Europe.
Early feedback from paramedics confirmed the importance of this innovation: “Paramedics told us they see real added value in a solution that is simple to integrate into their stressful routine, especially knowing that in stroke, every minute saved can mean the difference between life and death,” said Carmen de Jesús Gil, PhD, Clinical Studies Lead at ABCDx.
Behind this apparent simplicity is over a decade of R&D: the discovery of the optimal blood-biomarker panel, patent protection in the world’s largest markets, and the development of robust machine-learning algorithms validated in more than 1,000 patients.
“Stroke is a race against time. With this platform, our vision is to make brain diagnostics faster, simpler, and more reliable right at the ambulance,” said Jean-Charles Sanchez, CEO of ABCDx.
This pilot marks a key step in building a scalable diagnostic platform that could be deployed in ambulances worldwide to transform stroke care.
Investor Opportunity
Building on this milestone, ABCDx is currently raising its Series A round to accelerate CE-marking, regulatory submission, and global market entry. The company holds a strong IP portfolio across emergency brain diagnostics, including a recently granted U.S. patent on its traumatic brain injury (TBI) biomarker panel.
This strong foundation positions ABCDx to form strategic partnerships and pursue licensing opportunities across multiple indications. By validating the complete brain diagnostic platform in ambulances today, ABCDx is laying the foundation for tomorrow’s standard of care and opening a unique investment opportunity in one of the fastest-growing segments of medtech.
This article was originally published by IssueWire. Read the original article here.
